Back to search results

Mindfulness Training for Veterans with PTSD, Depression, or Anxiety

This study is for Veterans experiencing symptoms of anxiety, depression, or PTSD. It compares two mental health classes: Primary Care Brief Mindfulness Training (PCBMT), which teaches mindfulness meditation, and Moving Forward (MF), which focuses on problem-solving skills and building resilience. The goal is to see if these classes can reduce your symptoms and improve your overall well-being. To join, you must be enrolled in VA primary care and have significant psychological distress related to PTSD, depression, or anxiety. The study aims to enroll 300 participants and is currently unclear about its recruitment status.

Study design
This is a randomized controlled trial comparing two behavioral interventions. It plans to enroll 300 participants.
What's involved
You would attend four 90-minute classes, for a total of 360 minutes of classes. Your symptoms will be measured at baseline, 8 weeks, 16 weeks, and 24 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your symptoms will be monitored for up to 24 weeks after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06162741

Type I Hybrid Effectiveness-Implementation Trial of Primary Care Brief Mindfulness Training for Veterans

Recruiting
NAAges 18+InterventionalTreatment
VA Office of Research and Development
~300 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:Primary Care Brief Mindfulness Training (PCBMT)Moving Forward (MF)

At a glance

Recruiting sites
3 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Depression Anxiety and Stress Scale (DASS-21) Change
Measured over Up to 24 weeks: Baseline, 8 weeks, 16 weeks, 24 weeks

Conditions

Post Traumatic Stress Disorder (PTSD)
Depression
Anxiety

Explore related trials

AnxietyDepressionPost-Traumatic Stress DisorderPsychological Distress

Where it's being run

4 sites across 4 states
Arizona1
California1
Missouri1
New York1

Study leadership

  • Kyle Possemato, PhD · PRINCIPAL_INVESTIGATOR · Syracuse VA Medical Center, Syracuse, NY

Who to contact

Kyle Possemato, PhD
[email protected]
(315) 425-4400 · ext. 53551
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

enrolled in VA primary care through the local VA site
report clinically significant psychological distress as measured in at least one of three areas:
PTSD operationalized by 30 on the PCL-5 plus endorsing a criteria A stressor
depression operationalized as 10 on the PHQ-9
anxiety operationalized by 10 on the GAD-7
gross cognitive impairment
suicide attempt or desire to commit suicide in the last month
had a psychotherapy appointment outside of primary care within the last month and have future appointment scheduled
had a change in psychiatric medication outside of VHA primary care in the last 2 months
voice a preference to be directly referred to specialty mental health care

What this trial measures

  • Depression Anxiety and Stress Scale (DASS-21) ChangeUp to 24 weeks: Baseline, 8 weeks, 16 weeks, 24 weeks

    The Depression Anxiety and Stress Scale (DASS-21) is a widely used measurement for psychological symptoms and distress. It consists of 21 items measured on a 4-point scale. The three subscale scores for depression, anxiety, and stress are also valid measures of their constructs and will be used as secondary outcomes. Depression subscale range: 0-42 with higher scores meaning a worse outcome. Anxiety subscale range: 0-42 with higher scores meaning a worse outcome. Stress subscale range 0-21 with higher scores indicative of greater symptom severity.